To evaluate the respiratory and cardiovascular morbidities in the experimental group with daily consumption of Tannin-Niacin-apocynin in affected patients by coronavirus infection
In phase II, at first, 5 patients with non-serious presentations are included in a pilot-study with informed consent. The current-treatments are given to the patients in an open-labeled-approach and the combination drug is added on their treatment. If the results are approved the trial will continue with more patients up to 20% of all experimental-cases. If the results are approved again, the study will continue on all the cases according to the following statement.
Settings and conduct
80 patients confirmed for COVID-19 are recruited into two groups through the permuted block randomization approach. Each group included 40 cases.
Participants/Inclusion and exclusion criteria
Inclusion-criteria: Age more than 18 years, Clinical and paraclinical signs and symptoms for COVID19, inpatient-setting, Positive-PCR, Informed-consent
Exclusion-criteria: Pregnancy, hx of using ACEI and ARB-drugs, fludrocortisone, spironolactone, eplerenone, TCA, Simvastatin, MAO-inhibitors, serotonin-inhibitors, Triptamins, Alcoholism, Heart-Failure, Hepatic-Failure, renal-dysfunction, drug side-effects, Active-peptic-ulcer, Active-Bleeding
Experimental group includes inpatient COVID19cases with mild-to-moderate respiratory problems that are confirmed for corona infection. They give current treatment plus the three-drug combination of trial.
Control group includes the COVID19patients with mild-to-moderate respiratory problems that will be treated just by current-treatment.
Main outcome variables
Fever, PR, RR, BP